Intravenous Furosemide in the Management of Transient Tachypnea of Newborn

Abstract

Objective: To determine the mean length of hospital stay of term and late preterm infants with transient tachypnea of the newborn treated with intravenous Furosemide compared to the Control Group.

Study Design: Quasi-experimental study.

Place and Duration of Study: Combined Military Hospital, Kharian, from Apr to Oct 2016.

Methodology: All term and late preterm infants with transient tachypnea of new-borns were included in the study. One Group was given IV Furosemide, and the other was taken as control. Two doses of Furosemide were administered IV at 1 mg/kg 12 hours apart. The Control Group were given normal saline 01 ml/kg as a placebo 12 hours apart.

Results: It was found that the duration of tachypnea in the Study-Group was less than that of the Control-Group (49.4±7.4 h vs 76.7±4.5h, p-value <0.001). The requirement of oxygen was less in the Treatment Group (53.7±6.6h) as compared to the Control-Group (84.5±4.2h) (p<0.01). The duration of hospitalization in the Study-Group was 71.4±4.9 hours, and in the Control-Group was 100.0±3.7 hours (p-value <0.001).

Conclusion: Using intravenous Furosemide in neonates with transient tachypnea of newborns effectively reduces the hospital stay of term and late preterm patients. It reduced the tachypnea and, subsequently, the requirement for oxygen in patients with transient tachypnea in newborns.